In a report released today, Sean Dodge from RBC Capital maintained a Buy rating on Agilon Health (AGL – Research Report), with a price target of $8.00. The company’s shares closed yesterday at $6.48.
Dodge covers the Healthcare sector, focusing on stocks such as Evolent Health, R1 RCM, and Catalent. According to TipRanks, Dodge has an average return of -4.3% and a 43.84% success rate on recommended stocks.
In addition to RBC Capital, Agilon Health also received a Buy from JMP Securities’s Constantine Davides in a report issued today. However, on the same day, Evercore ISI maintained a Hold rating on Agilon Health (NYSE: AGL).
See the top stocks recommended by analysts >>
AGL market cap is currently $2.55B and has a P/E ratio of -28.33.
Based on the recent corporate insider activity of 44 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of AGL in relation to earlier this year. Last month, Ronald A. Williams, a Director at AGL bought 1,100,000.00 shares for a total of $1,400,000.00.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Agilon Health (AGL) Company Description:
Agilon Health Inc is transforming healthcare by empowering community-based physicians with the resources and expertise they need to innovate the payment and delivery of care for seniors. The company enables physicians to create their own Medicare-centric globally capitated line of business.
Read More on AGL:
